Tocilizumab

Drug Profile

Tocilizumab

Alternative Names: Actemra; Anti-IL-6 receptor antibody - Chugai; Anti-interleukin-6 receptor antibody - Chugai; Atlizumab; HPM-1; MRA; MRA - Chugai; MRA-SC; R-1569; RG-1569; rhPM-1; RO4877533; RoActemra

Latest Information Update: 09 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chugai Pharmaceutical; Osaka University
  • Developer Assistance Publique Hopitaux de Paris; Charite of Berlin; Chugai Pharmaceutical; Hospital for Special Surgery; JW Pharmaceutical; Roche; University Hospital Inselspital; University of Bern; University of Pittsburgh
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant lymph node hyperplasia; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Giant lymph node hyperplasia; Juvenile rheumatoid arthritis; Rheumatoid arthritis
  • Registered Giant cell arteritis
  • Preregistration Vasculitis
  • Phase III Osteoarthritis; Systemic scleroderma
  • Phase II Amyotrophic lateral sclerosis; Dermatomyositis; Polymyalgia rheumatica; Polymyositis; Schnitzler syndrome
  • Phase I Chronic lymphocytic leukaemia
  • Discontinued Ankylosing spondylitis; Crohn's disease; Multiple myeloma; Pancreatic cancer; Systemic lupus erythematosus

Most Recent Events

  • 26 Jul 2017 Updated adverse events data from the phase III GiACTA trial in Giant cell arteritis released by Genentech
  • 21 Jul 2017 Preregistration for Giant cell arteritis (Combination therapy) in European Union (SC)
  • 21 Jul 2017 CHMP recommends approval of tocilizumab for Giant cell arteritis in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top